Aadi Bioscience Q1 2024 Earnings Report $2.79 -0.07 (-2.45%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Aadi Bioscience EPS ResultsActual EPS-$0.68Consensus EPS -$0.66Beat/MissMissed by -$0.02One Year Ago EPSN/AAadi Bioscience Revenue ResultsActual Revenue$5.35 millionExpected Revenue$6.41 millionBeat/MissMissed by -$1.06 millionYoY Revenue GrowthN/AAadi Bioscience Announcement DetailsQuarterQ1 2024Date5/8/2024TimeN/AConference Call ResourcesPress ReleaseAADI Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Aadi Bioscience Earnings Headlines3 US Penny Stocks With Market Caps Over $30M To WatchFebruary 21 at 5:20 PM | uk.finance.yahoo.comAadi Bioscience appoints Dornan as Chief Scientific OfficerFebruary 19 at 12:30 AM | markets.businessinsider.comWatch This Robotics Demo Before March 17thJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."February 22, 2025 | Brownstone Research (Ad)Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific OfficerFebruary 18, 2025 | prnewswire.comAadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025February 5, 2025 | prnewswire.comAadi Bioscience Leads 3 Promising US Penny StocksDecember 23, 2024 | uk.finance.yahoo.comSee More Aadi Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aadi Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aadi Bioscience and other key companies, straight to your email. Email Address About Aadi BioscienceAadi Bioscience (NASDAQ:AADI), a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.View Aadi Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
